<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ferric hexacyanoferrate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ferric hexacyanoferrate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ferric hexacyanoferrate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11261" href="/d/html/11261.html" rel="external">see "Ferric hexacyanoferrate: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="134967" href="/d/html/134967.html" rel="external">see "Ferric hexacyanoferrate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F216875"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Radiogardase</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F216890"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote</li></ul></div>
<div class="block doa drugH1Div" id="F216876"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e11d9cc3-0241-48f4-8c16-80f8d4df7103">Internal contamination with radioactive cesium and/or radioactive or nonradioactive thallium</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Internal contamination with radioactive cesium and/or radioactive or nonradioactive thallium:</b>
<b>Note:</b> Treatment should begin as soon as possible following exposure (Rump 2018); however, treatment is also effective if therapy is delayed (Sun 2012). Treatment typically continues for ≥30 days (Kazzi 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">Cesium exposure: <b>Oral:</b> 1 to 3 g 3 times daily and continued for ≥30 days (as needed based on quantitative and radiologic evaluation of cesium elimination); doses up to 10 to 12 g per day have been required in significantly contaminated adults (Hoffman 2018; IAEA 1988; REMM 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">Thallium exposure: <b>Oral:</b> 3 g 3 times daily <b>or </b>150 to 250 mg/kg/day in 2 to 4 divided doses and continued until total urinary thallium concentrations are &lt;0.5 mg/day (Hoffman 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling:</i> Dosing in the prescribing information may not reflect current clinical practice. <b>Oral:</b> 3 g 3 times daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990222"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, ferric hexacyanoferrate is not systemically absorbed.</p></div>
<div class="block doha drugH1Div" id="F50987527"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, effectiveness may be decreased due to decreased biliary excretion of cesium and thallium.</p></div>
<div class="block doe drugH1Div" id="F216877"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F216886"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="134967" href="/d/html/134967.html" rel="external">see "Ferric hexacyanoferrate: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e11d9cc3-0241-48f4-8c16-80f8d4df7103">Internal contamination with radioactive cesium and/or radioactive or nonradioactive thallium</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Internal contamination with radioactive cesium and/or radioactive or nonradioactive thallium: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Treatment should begin as soon as possible following exposure (Rump 2018); however, treatment is also effective if therapy is delayed (Sun 2012). Treatment typically continues for ≥30 days (Kazzi 2015). Consult clinical toxicologist.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: Very limited data available; expert opinion: Oral: 150 to 250 mg/kg/day in 2 to 4 divided doses (Hoffman 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 12 years: Oral: 1,000 mg 3 times daily (AAP [Shenoi 2020]; Hoffman 2019; REMM 2021; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Cesium exposure: Oral: 1,000 to 3,000 mg 3 times daily and continued for ≥30 days (as needed based on quantitative and radiologic evaluation of cesium elimination) (REMM 2021); in adults, doses up to 10 to 12 <b>g</b>/day have been required in significant contamination events (AAP [Shenoi 2020]; Hoffman 2019; IAEA 1988; REMM 2021).</p>
<p style="text-indent:-2em;margin-left:6em;">Thallium exposure: Oral: 3,000 mg 3 times daily or 150 to 250 mg/kg/day in 2 to 4 divided doses and continued until total urinary thallium concentrations are &lt;0.5 mg/day, or longer if patient is still symptomatic (AAP [Shenoi 2020]; Hoffman 2019; REMM 2021; manufacturer's labeling).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51110029"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, ferric hexacyanoferrate is not systemically absorbed.</p></div>
<div class="block dohp drugH1Div" id="F51110030"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, effectiveness may be decreased due to decreased biliary excretion of cesium and thallium.</p></div>
<div class="block adr drugH1Div" id="F216851"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Constipation (24%), fecal discoloration (blue), gastric distress</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hypokalemia (7%)</p></div>
<div class="block coi drugH1Div" id="F216863"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications in the manufacturer’s labeling. </p></div>
<div class="block war drugH1Div" id="F216849"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discoloration: Feces will turn blue; if capsule contents are opened and eaten with food, oral mucosa and detention may also be colored blue.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac arrhythmias: Use with caution in patients with preexisting cardiac arrhythmias; may cause electrolyte imbalances.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalances: May bind to electrolytes in the GI tract. Use with caution in patients with electrolyte imbalances.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric immotility: Use with caution in patients with decreased gastric motility; constipation should be avoided to prevent increased radiation absorption from the GI tract. Increase dietary fiber or take with fiber laxative to decrease constipation. The cesium- or thallium-bound ferric hexacyanoferrate insoluble complex must move through the GI tract in a timely manner so that the associated radiation is not absorbed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation exposure: Patients should be instructed to minimize radiation exposure to others or re-exposure to self.</p>
<p style="text-indent:-2em;margin-left:4em;">• Radiation toxicity: Appropriate use: Ferric hexacyanoferrate increases the rate of elimination of thallium and cesium; it does not treat complications of radiation exposure. Supportive treatment for radiation toxicity should be given concomitantly. Additional decontamination and/or treatment may be needed if exposure to other radioactive isotopes is known or suspected. Radiation elements that do not undergo enterohepatic recirculation are not removed by ferric hexacyanoferrate.</p></div>
<div class="block foc drugH1Div" id="F216858"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Radiogardase: 0.5 g</p></div>
<div class="block geq drugH1Div" id="F216847"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F24145338"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Radiogardase Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 g (per each): $3.42</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F216860"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> In critically ill patients who cannot swallow, capsules may be opened and administered by orogastric or nasogastric tube. Also, the capsules may be opened and mixed with bland food or liquid. Administer with food to stimulate excretion of cesium or thallium. Increase dietary fiber or take with fiber laxative to decrease constipation (Hoffman 2018).</p></div>
<div class="block admp drugH1Div" id="F52613801"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food to stimulate excretion of cesium or thallium. Capsules may be opened and mixed with bland food or liquid. In critically ill patients who cannot swallow, capsules may be opened and administered by orogastric or nasogastric tube (Hoffman 2019). Increase dietary fiber or take with fiber laxative to decrease constipation.</p></div>
<div class="block use drugH1Div" id="F216859"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Internal contamination:</b> Ferric hexacyanoferrate (also known as Prussian blue) is an orally available cation exchange resin that is indicated for the treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or nonradioactive thallium to increase their rates of elimination.</p></div>
<div class="block cyt drugH1Div" id="F13299321"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F216853"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block foi drugH1Div" id="F216872"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food may increase effectiveness by stimulating bile secretion and thereby increasing the amount of cesium or thallium available to bind with ferric hexacyanoferrate. Management: Administer with food to stimulate excretion of cesium or thallium.</p></div>
<div class="block pri drugH1Div" id="F216865"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Ferric hexacyanoferrate is not absorbed from the gastrointestinal tract and is not expected to affect the fetus. Cesium-137 crosses the placenta; in one case, reported levels were equal in the mother and the neonate. Thallium also crosses the placenta; fetal death and failure to thrive have been reported. Toxicity from exposure to thallium or radioactive cesium is expected to be greater than the risk of toxicity to ferric hexacyanoferrate. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey, 2003).</p></div>
<div class="block brc drugH1Div" id="F216866"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Excretion of ferric hexacyanoferrate in breast milk is not known, but would not be expected. Cesium and thallium are excreted in breast milk; internally contaminated mothers should not breast-feed.</p></div>
<div class="block dic drugH1Div" id="F216867"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with food. A high-fiber diet or fiber laxative is recommended to avoid constipation.</p></div>
<div class="block mop drugH1Div" id="F216856"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bowel movements; CBC with differential and platelets and electrolytes weekly </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Baseline cesium and/or thallium exposure (whole body counting and/or bioassay, feces or urine sample); urine and fecal cesium and/or thallium weekly during therapy; residual whole body radioactivity after 30 days of treatment</p></div>
<div class="block pha drugH1Div" id="F216848"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">The ferric hexacyanoferrate lattice preferentially binds cesium and thallium isotopes in the gastrointestinal tract following their ingestion or excretion in the bile (thereby, blocking reabsorption). The resulting complex is eliminated in the feces reducing the absorption of thallium or the radioactive residence time of cesium (Kazzi 2015).</p></div>
<div class="block phk drugH1Div" id="F216862"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Ferric hexacyanoferrate: Oral: None </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cesium-137: Effective: Adults: 80 days, decreased by 69% with ferric hexacyanoferrate; adolescents: 62 days, decreased by 46% with ferric hexacyanoferrate; children: 42 days, decreased by 43% with ferric hexacyanoferrate </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nonradioactive thallium: Biological: 8 days; with ferric hexacyanoferrate: 3 days </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Ferric hexacyanoferrate: Feces (99%, unchanged) (Radiogardase, 2008)</p></div>
<div class="block phksp drugH1Div" id="F51192549"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: May be less effective because of decreased biliary excretion of cesium and thallium.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49939486"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Radiogardase cs</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Radiogardase cs</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Radiogardase</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Radiogardase</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Radiogardase cs</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30489370">
<a name="30489370"></a>Adams TG, Casagrande R. Modeling the optimum Prussian blue treatment for acute radiation syndrome following 137Cs ingestion. <i>Health Phys</i>. 2019;116(1):88-95. doi: 10.1097/HP.0000000000000966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/30489370/pubmed" id="30489370" target="_blank">30489370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18242038">
<a name="18242038"></a>Faustino PJ, Yang Y, Progar JJ, et al. Quantitative determination of cesium binding to ferric hexacyanoferrate: Prussian blue. <i>J Pharm Biomed Anal</i>. 2008;47(1):114-125. doi: 10.1016/j.jpba.2007.11.049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/18242038/pubmed" id="18242038" target="_blank">18242038</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hoffman RS. Antidotes in depth: Prussian blue. In: Goldfrank LR, ed. <i>Goldfrank’s Toxicologic Emergencies. </i>11th ed. McGraw-Hill; 2019:1283-1287.</div>
</li>
<li>
<div class="reference">
                  International Atomic Energy Agency (IAEA). The Radiological Accident in Goiânia. https://www-pub.iaea.org/MTCD/Publications/PDF/Pub815_web.pdf. Published September 1988. Accessed February 7, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25455668">
<a name="25455668"></a>Kazzi Z, Buzzell J, Bertelli L, Christensen D. Emergency department management of patients internally contaminated with radioactive material. <i>Emerg Med Clin North Am</i>. 2015;33(1):179-196. doi:10.1016/j.emc.2014.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/25455668/pubmed" id="25455668" target="_blank">25455668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25608705">
<a name="25608705"></a>Mohammad A, Yang Y, Khan MA, Faustino PJ. Long-term stability study of Prussian blue-A quality assessment of water content and cyanide release. <i>Clin Toxicol (Phila).</i> 2015;53(2):102-107. doi:10.3109/15563650.2014.998337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/25608705/pubmed" id="25608705" target="_blank">25608705</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Radiogardase (Prussian blue insoluble) [prescribing information]. Berlin, Germany: HEYL Chemisch-pharmazeutische Fabrik GmbH &amp; Co; August 2014.</div>
</li>
<li>
<div class="reference">
                  Radiogardase (Prussian blue insoluble) [prescribing information]. Berlin, Germany: HEYL Chemisch-pharmazeutische Fabrik GmbH &amp; Co; March 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30086798">
<a name="30086798"></a>Rump A, Becker B, Eder S, Lamkowski A, Abend M, Port M. Medical management of victims contaminated with radionuclides after a "dirty bomb" attack. <i>Mil Med Res</i>. 2018;5(1):27. doi:10.1186/s40779-018-0174-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/30086798/pubmed" id="30086798" target="_blank">30086798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs Used to Treat Pediatric Emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22175787">
<a name="22175787"></a>Sun TW, Xu QY, Zhang XJ, et al. Management of thallium poisoning in patients with delayed hospital admission. <i>Clin Toxicol (Phila)</i>. 2012;50(1):65-69. doi:10.3109/15563650.2011.638926<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/22175787/pubmed" id="22175787" target="_blank">22175787</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services, Radiation Emergency Medical Management (REMM). Radiation countermeasures for treatment of internal contamination. <a href="https://remm.hhs.gov/isotopestable.pdf" target="_blank">https://remm.hhs.gov/isotopestable.pdf</a>. Accessed January 18, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18226478">
<a name="18226478"></a>Yang Y, Faustino PJ, Progar JJ, et al. Quantitative determination of thallium binding to ferric hexacyanoferrate: Prussian blue.<i> Int J Pharm</i>. 2008;353(1-2):187-194. doi: 10.1016/j.ijpharm.2007.11.031.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-hexacyanoferrate-drug-information/abstract-text/18226478/pubmed" id="18226478" target="_blank">18226478</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8626 Version 100.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
